BioAge Labs will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, a novel oral NLRP3 inflammasome inhibitor. The drug targets inflammation linked to atherosclerotic cardiovascular disease and retinal diseases like diabetic macular edema. The event will feature presentations by BioAge leadership and four medical experts discussing the drug's mechanism and therapeutic potential. Phase 2 data for cardiovascular risk is expected in the second half of 2026, with retinal disease data anticipated in mid-2027.
Equinor ASA will begin the third tranche of its 2026 share buyback program on July 23, 2026, with a budget of up to $1.125 billion. This tranche includes $371.3 million worth of shares to be bought from the market and will conclude by October 26, 202...
Enigmatig Limited has invested in KUNGFULAND, the first scripted feature-length action-comedy co-produced by Singapore and Canada using virtual production technology. Filming began in June 2026 in Singapore, blending advanced LED wall technology with...
Diana Burgon of Berkshire Hathaway HomeServices Bayside Realty was named to the 2025 Honor Society, recognizing the top 17% of sales professionals in the network. This award highlights her outstanding sales performance and dedication to clients. Sinc...
TSMC is investing $200 billion in U.S. semiconductor manufacturing following President Trump's 2025 return, driven by political pressure to produce chips domestically. This expansion raises production costs by 20-50% compared to Taiwan, squeezing pro...
Norsk Hydro reported a strong Q2 2026 with adjusted EBITDA rising to NOK 8,923 million, driven by higher aluminum prices, product premiums, and improved recycling earnings. Despite challenges like lower energy production and a stronger Norwegian kron...
